Ipilimumab vs Osimertinib
Ipilimumab vs Osimertinib: Overview
This comparison examines the pharmacological differences between Ipilimumab and Osimertinib.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Osimertinib — 48 hours.
Chemical Properties
Molecular Formula: Osimertinib — C28H33N7O2.
Molecular Weight: Osimertinib — 499.6050 g/mol.
Type: Ipilimumab — Antibody; Osimertinib — Small molecule.